文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

苯磺酸瑞马唑仑减少老年无痛胃肠镜低氧血症:多中心随机对照试验方案

Remimazolam besylate reduces hypoxemia during painless gastrointestinal endoscopy in elderly patients: study protocol for a multicenter, randomized, controlled trial.
PubMed 文献 · Trials · 2026-06-12

主要结局为术中低氧血症发生率,旨在评估瑞马唑仑是否降低呼吸抑制并改善老年患者安全性。

要点

  • 比较苯磺酸瑞马唑仑与丙泊酚在老年无痛胃肠镜中的低氧血症发生率。
  • 主要结局低氧血症定义为SpO₂≥75%且<90%持续<60秒。

核心结论

  • 该试验旨在评估苯磺酸瑞马唑仑是否减少老年无痛胃肠镜中的呼吸抑制并改善安全性。
  • 结果可能为优化高危老年人群的镇静策略提供证据。

研究设计与样本

  • 多中心、双盲、平行、随机对照试验。
  • 按1:1随机接受苯磺酸瑞马唑仑(0.15 mg/kg)联合舒芬太尼或丙泊酚(1.5 mg/kg)联合舒芬太尼。
  • 按年龄(65-70岁 vs. 70-75岁)和3家研究机构分层。

关键数值与推荐

  • 主要结局为术中低氧血症发生率,定义为SpO₂≥75%且<90%持续<60秒的任何事件。
  • 次要结局包括低氧血症程度、紧急气道管理、丙泊酚用量、血流动力学稳定性、不自主体动、操作/恢复时间和临床医生满意度。

临床怎么用

  • 若试验证实瑞马唑仑优势,可为老年无痛胃肠镜镇静提供更安全的选择。
  • 需关注主要结局定义的特定低氧血症范围(SpO₂≥75%且<90%持续<60秒)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hypoxemia and circulatory depression are common complications in elderly patients undergoing procedure sedation anesthesia (PSA) for gastrointestinal (GI) endoscopy. Remimazolam besylate, a novel ultra-short-acting benzodiazepine, is postulated to offer a superior safety profile with reduced respiratory depressant effects compared to propofol. This study aims to compare the incidence of hypoxemia of remimazolam besylate versus propofol for painless GI endoscopy in elderly patients through a multicenter randomized controlled trial. METHODS: This study is a multicenter, double-blind, parallel, randomized, controlled trial. Six hundred seventy elderly patients scheduled for GI endoscopy under PSA are enrolled at three medical institutions in China from 2025 to 2027. Patients will be randomized 1:1 to receive remimazolam besylate (0.15 mg/kg) plus sufentanil vs propofol (1.5 mg/kg) plus sufentanil, stratified by age (65-70 vs.70-75 years old) and 3 research institution. The primary outcome is the incidence of intraoperative hypoxemia, defined as any event where peripheral oxygen saturation (SpO₂) is ≥ 75% and < 90%, lasting for less than 60 s. Secondary outcomes include hypoxemia degree, emergency airway management, propofol consumption, hemodynamic stability, involuntary body movements, procedure/recovery times, and clinician satisfaction. DISCUSSION: This trial evaluates whether remimazolam besylate reduces respiratory depression and improves safety profiles in elderly patients during painless GI endoscopy. It may provide evidence for optimizing sedation strategies in high-risk elderly populations. TRIAL REGISTRATION: Chinese Clinical Trial Registry ChiCTR2500110081, registrated on September 30, 2025.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Zhang FY, Ma Z, Zhang W, et al. Remimazolam besylate reduces hypoxemia during painless gastrointestinal endoscopy in elderly patients: study protocol for a multicenter, randomized, controlled trial. Trials. 2026. PMID: 42277954. doi:10.1186/s13063-026-09832-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。